Federal Circuit remands Skelaxin infringement case

18-05-2015

The US Court of Appeals for the Federal Circuit has vacated and remanded a case between Classen Immunotherapies and Elan Pharmaceuticals, to determine whether Elan infringed a Classen patent when it tried to change the product label for one of its drugs.


US Court of Appeals for the Federal Circuit, US District Court for the District of Maryland, Classen Immunotherapies, Elan Pharmaceuticals, Skelaxin

LSIPR